Cargando…
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
BACKGROUND AND OBJECTIVES: Live cell-based assay (CBA) can detect acetylcholine receptors (AChRs) or muscle-specific tyrosine kinase (MuSK) antibodies (Abs) in a proportion of patients with radioimmunoassay (RIA)-double seronegative myasthenia gravis (dSN-MG). A commercial fixed CBA for AChR and MuS...
Autores principales: | Spagni, Gregorio, Gastaldi, Matteo, Businaro, Pietro, Chemkhi, Zeineb, Carrozza, Cinzia, Mascagna, Giovanni, Falso, Silvia, Scaranzin, Silvia, Franciotta, Diego, Evoli, Amelia, Damato, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621337/ https://www.ncbi.nlm.nih.gov/pubmed/36270951 http://dx.doi.org/10.1212/NXI.0000000000200038 |
Ejemplares similares
-
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019) -
Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015) -
Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016) -
Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023) -
Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)